These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 7338825)

  • 1. Initial human trials with an investigational new drug (phase I and 2): planning an management.
    Vaidya AB; Vaidya RA
    J Postgrad Med; 1981 Oct; 27(4):197-213. PubMed ID: 7338825
    [No Abstract]   [Full Text] [Related]  

  • 2. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 3. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on ACCP position statement on the use of microdosing in the drug development process.
    Rowland M
    J Clin Pharmacol; 2007 Dec; 47(12):1595-6; author reply 1597-8. PubMed ID: 18048576
    [No Abstract]   [Full Text] [Related]  

  • 5. The ethics of phase I pediatric oncology trials.
    Ackerman TF
    IRB; 1995; 17(1):1-5. PubMed ID: 11653060
    [No Abstract]   [Full Text] [Related]  

  • 6. The significance of properly designed pre-clinical studies in the clinical evaluation of new drugs.
    Garrett ER
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):6-20. PubMed ID: 4924331
    [No Abstract]   [Full Text] [Related]  

  • 7. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 8. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?
    Boers M
    Arthritis Rheum; 2003 Jun; 48(6):1481-3. PubMed ID: 12794813
    [No Abstract]   [Full Text] [Related]  

  • 10. [Goal and tasks of age-related (pediatric) pharmacology].
    Markova IV; Gusel' VA
    Farmakol Toksikol; 1983; 46(2):11-20. PubMed ID: 6343114
    [No Abstract]   [Full Text] [Related]  

  • 11. The ethical approach to phase II clinical trials in oncology.
    Dion S
    Drugs Exp Clin Res; 1986; 12(1-2-3):41-2. PubMed ID: 11650153
    [No Abstract]   [Full Text] [Related]  

  • 12. The ethical approach to phase I clinical trials in oncology.
    Durry G; Dion S
    Drugs Exp Clin Res; 1986; 12(1-2-3):21-2. PubMed ID: 11650152
    [No Abstract]   [Full Text] [Related]  

  • 13. ITT in respect to GCP: a matter of diligence.
    Van der Weijden F; Slot DE; Rosema M; Timmerman M
    J Clin Periodontol; 2008 Aug; 35(8):681-2. PubMed ID: 18727741
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 15. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical considerations in planning and conducting clinical trials with investigational or marketed drugs.
    Spilker B
    Clin Neuropharmacol; 1983; 6(4):325-47. PubMed ID: 6661731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.